97 results on '"Hassel, Jessica Cecile"'
Search Results
2. COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer
3. S100 as Serum Tumor Marker in Advanced Uveal Melanoma
4. Spiny Keratoderma der Hand‐ und Fußflächen – einmal gesehen, nie wieder vergessen
5. Spiny keratoderma of the palms and soles – once seen, never forgotten
6. Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM).
7. Multicenter real-world data of adjuvant treatment and disease outcome of patients with melanoma with high-risk of recurrence.
8. Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAFV600-mutant melanoma: Updated data from the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA.
9. Randomized phase 3 trial of IO102-IO103 plus pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic melanoma.
10. The GERMELATOX-A (Dermatologic Cooperative Oncology Group): Study attitude of German melanoma patients towards toxicity during adjuvant treatment.
11. Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAFᵛ⁶⁰⁰-mutant melanoma : Updated data from the multicenter, multinational, prospective, non-interventional longitudinal study BERINGᴹᴱᴸᴬᴺᴼᴹᴬ
12. Vemurafenib-induced granuloma annulare
13. Non-bullous neutrophilic lupus erythematosus: Case report of a rare entity
14. Nicht-bullöser neutrophiler Lupus erythematodes: Fallbericht einer seltenen Entität Non-bullous neutrophilic lupus erythematosus: Case report of a rare entity
15. Characterization of liver function tests (LFTs) following tebentafusp (tebe) in previously treated (2L+) metastatic uveal melanoma (mUM) patients (pts).
16. Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator’s choice (IC) in first-line metastatic uveal melanoma.
17. Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in patients (pts) with previously treated (2L+) metastatic uveal melanoma (mUM).
18. Encorafenib plus Binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutant melanoma: First data of the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA.
19. Results from the phase Ib of the SENSITIZE trial combining domatinostat with pembrolizumab in advanced melanoma patients refractory to prior checkpoint inhibitor therapy.
20. Overall survival benefit from tebentafusp in patients with best response of progressive disease.
21. Caspar Bartholin
22. Caspar Bartholin (1655–1738)
23. A shared tumor-antigen RNA-lipoplex vaccine with/without anti-PD1 in patients with checkpoint-inhibition experienced melanoma.
24. A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2).
25. Autoantibodies as predictors for survival and immune-related adverse events in checkpoint inhibition therapy of metastasized melanoma.
26. Checkpoint inhibitor treatment in patients with isolated in-transit melanoma metastases.
27. Serio - Side Effect Registry in Immuno-Oncology
28. A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2).
29. Subkutane Endometriose als Imitator einer Melanom‐Metastase
30. Sustainable responses in metastatic melanoma patients with/without brain metastases after immunotherapy induced CR.
31. Evaluation of radiotherapeutic and immune-modulatory response to whole brain radiotherapy or stereotactic radiosurgery in patients with brain metastases from malignant melanoma treated with or without ipilimumab (ELEKTRA).
32. Subcutaneous endometriosis mimicking melanoma metastasis
33. Charakterisierung von Arthralgien unter PD-1-Inhibitor-Therapie
34. COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer
35. The utility of chemotherapy after immunotherapy failure in metastatic melanoma: A multicenter case series.
36. BRAF/MEK inhibition in melanoma patients with rare BRAF mutations.
37. BRAF/MEK inhibition in melanoma patients with rare BRAF mutations
38. Radiosensibilisierung durch BRAF Inhibitoren
39. Radiosensibilisierung durch BRAF Inhibitoren
40. Radiosensitization by BRAF inhibitors
41. Investigation of the immune infiltrate of melanoma metastases under immune checkpoint inhibition.
42. First-line (1L) avelumab treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Preliminary data from an ongoing study.
43. COOLHAIR: A prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing neoadjuvant chemotherapy for early breast cancer.
44. Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP).
45. Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP).
46. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders (AD) or major toxicity with ipilimumab (IPI).
47. Patientin mit lividen Maculae an der Stirn nach photodynamischer Therapie
48. Livid macules on the forehead after photodynamic therapy
49. Phase II trial of ipilimumab in patients with advanced melanoma and spontaneous preexisting immune response to NY-ESO-1 (CTLA-4 NY-ESO-1).
50. Effect of nivolumab (NIVO) on quality of life (QoL) in patients (pts) with treatment-naïve advanced melanoma (MEL): Results of a phase III study (CheckMate 066).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.